Shareholder Firm Probes Medline Over Undisclosed Manufacturing Violations, Failed Contamination Investigations
MDLN sits 27% above its 52-week low of $32.815.
Summary
Shareholder rights firm Hagens Berman Sobol Shapiro (HBSS) has launched an investigation into Medline Inc. for allegedly misleading investors about its manufacturing quality controls and FDA compliance. This probe follows reports of undisclosed manufacturing violations, failed contamination investigations, and a May 28 FDA warning letter citing CGMP violations and objectionable microorganisms. The article notes these revelations, including a facility shutdown last October, already caused a $2.2 billion market cap decline. The investigation introduces new legal risk and potential for litigation stemming from these regulatory issues.
At the time of this announcement, MDLN was trading at $41.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.8B. The 52-week trading range was $32.82 to $50.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.